Abstract Library

#2262 Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome

Introduction: Telotristat ethyl (TE) is a treatment for carcinoid syndrome (CS) diarrhea used in combination with somatostatin analog (SSA) therapy. In the Phase 3, randomized, placebo-controlled, double-blind TELESTAR and TELECAST studies, CS patients received TE at 250 mg 3 times per day (tid), 500 mg tid, or placebo tid in addition to SSAs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Dillon J, Kulke M, Warner R, Bergsland E, Welin S,

Keywords: telotristat ethyl, somatostatin analogs, carcinoid syndrome,

#1942 Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial

Introduction: TELECAST assessed telotristat ethyl (TE), a tryptophan hydroxylase inhibitor, in patients (pts) with carcinoid syndrome (CS) with ≥1 CS symptom/sign and a mean 2.5 bowel movements (BMs) per day. Pts were somatostatin analog treated (89%), with gastrointestinal (90%; [diarrhea, 70%]) and cardiac disorders (42%), including carcinoid heart disease. At Week (W) 12, TE (250 and 500 mg 3×/day; tid) significantly reduced urinary 5-hydroxyindoleacetic acid (u5-HIAA) and BMs/day vs placebo (pbo) (p≤0.008). After W12, pts crossed over to an open-label extension (OLE) with TE 500 mg tid (W13–48).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Benavent M, Perros P, Srirajaskanthan R, Warner R,

Keywords: serotonin, safety,

#1353 A Case Series of 27 Primary Ovarian Neuroendocrine Tumors

Introduction: Primary neuroendocrine tumors of the ovary are rare and often found incidentally.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Weinstein Y, Heskel M, Mares A, Deligdisch L, Warner R,

Keywords: Ovarian Carcinoid, Neuroendocrine,

#1272 Telotristat Etiprate Appears to Halt Carcinoid Heart Disease

Introduction: Carcinoid Heart Disease (CHD) is a serious complication of the Carcinoid Syndrome (in as many as 50% of patients during the course of their disease). 46% of cases operated with bioprosthetic valves develop recurrent carcinoid valvulopathy on the newly implanted tissue valves. Until now, only mechanical prosthetic valves avoid recurrent fibrosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Zacks J

Authors: Zacks J, Lavine R, Ratner L, Warner R,

Keywords: carcinoid heart disease, valve, heart failure, carcinoid syndrome, prosthetic valves, telotristat etiprate,

#1021 Recurrent Carcinoid Valvulopathy after Bioprosthetic Valve Surgery

Introduction: Carcinoid heart disease (CHD) typically affects right-sided cardiac structures causing leaflet thickening, retraction and valve dysfunction requiring surgery.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Zacks J, Canovas E, Lavine R, Warner R,

Keywords: valves, recurrent carcinoid disease, serotonin,